HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
GLUE
Monte Rosa Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $1.31B
Market Cap
$1.31B
Enterprise Val
$721.4M
P/E Ratio
-8.13
P/B Ratio
2.69
Trailing PEG (1Y)
-0.04
As Of
Aug 13, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$487.3M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-43.31%
Return on Assets-27.59%
Current Ratio10.58
Debt/Equity0.08
LT Debt/Equity0.07
Revenue Per Share0.11

Income Statement

Jun 30, 2026
Revenue$9.0M
Cost of Revenue$0.00
Gross Profit$9.0M
R&D$48.0M
SG&A$10.1M
Operating Expenses$58.1M
Operating Income-$49.1M
Interest Expense$0.00
Tax Expense$208.0K
Net Income-$43.4M
EPS (Basic)$-0.43
EPS (Diluted)$-0.43
EBIT-$43.2M
EBITDA-$41.3M
Consolidated Income-$43.4M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$95.0M
Accounts Receivable$4.9M
Inventory$0.00
Current Assets$631.4M
LT Investments$0.00
Property, Plant & Equipment$54.0M
Intangibles$0.00
Non-Current Assets$59.8M
Total Assets$691.2M
Accounts Payable$7.2M
Current Debt$4.6M
Current Liabilities$59.7M
LT Debt$33.4M
Non-Current Liabilities$144.2M
Total Liabilities$203.9M
Total Debt$38.0M
Retained Earnings-$565.1M
Shareholder Equity$487.3M
Shares Outstanding84,479,418

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$44.1M
Investing Cash Flow-$28.9M
Financing Cash Flow$3.2M
CapEx-$4.7M
Free Cash Flow-$48.8M
Depreciation & Amort.$1.9M
Stock-Based Comp$6.0M
Acquisitions / Disposals$0.00
Investment Activity-$24.1M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$3.2M
Dividends Paid$0.00
Net Change in Cash-$69.8M
Data cached · Meta live · Daily live · Statements live · TTL 24h